PCG Advisory Announces PCG Spotlight Series Conference on November 21st

8 months ago

Conference will Showcase 8 Unique Life Science Companies in NYC from 11:45am – 3:30pm ET

New York City, NY, Nov. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- PCG Advisory, Inc., a leading investor relations, strategic communications and cutting-edge digital marketing firm, today announced its PCG Spotlight Series Conference taking place on Thursday, November 21st at the Harvard Club, 35 West 44th Street, NYC. Company presentations will be held from 11:45am ET – 3:30pm ET.

“Each of the eight companies presenting at our Spotlight Series Conference has an innovative approach to its mission. With 20 minute presentations and networking among the participants and a high quality group of investors, this is a great opportunity for attendees to get to know the managements and missions of these unique companies,” said Jeff Ramson, Founder and CEO of PCG Advisory.

Interested investors may RSVP to ksmith@pcgadvisory.com to attend.
The eight participating life science companies include:

Emerald Bioscience, Inc.: Biotech company focused on the development of cannabinoid-based therapeutics to address global medical indications.  Emerald is currently the only cannabinoid company with a multi-cannabinoid platform addressing diseases of the eye with multi-billion-dollar targets of urgent medical need.

Emerald Organic Products, Inc.: Developed and commercialized a line of vitamins and supplements with certain proprietary cannabidiol (CBD) health and wellness products. Recently signed agreement for the exclusive, worldwide license of several cutting-edge treatments, including Phase 3-ready therapies for ADHD and skin regeneration.

Exicure, Inc.: A pioneer in gene regulatory and immunotherapeutic drugs developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on proprietary Spherical Nucleic Acid (SNA™) constructs.

Myomo, Inc.: A wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury.

Navidea Biopharmaceuticals, Inc.: A biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.  Navidea is developing multiple precision-targeted products and is focused on solving the many problems presented by Rheumatoid Arthritis (“RA”) and other inflammatory conditions.

Nephros, Inc.: A commercial stage company that develops and sells high-performance water purification products to the medical device and commercial markets.

Soligenix, Inc.: A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States with 2 active Phase 3 assets in clinical trials to treat cutaneous T-cell lymphoma; and oral mucositis in head and neck cancer.

Zyversa Therapeutics, Inc.: Clinical stage biopharmaceutical company developing first-in-class drugs, initially targeting the $60+ billion anti-inflammatory drug market and the $13+ billion renal drug market. ZyVersa’s lead anti-inflammatory candidate, a novel inflammasome inhibitor, has potential to treat a broad range of inflammatory diseases. ZyVersa’s lead renal candidate, a disease-modifying cholesterol efflux mediator, removes excess cholesterol from the kidneys that causes damage and dysfunction. A Phase 2a trial is expected to begin Q1-2020.

About PCG Advisory, Inc.

PCG Advisory is a leading investor relations firm dedicated to the delivery of top-tier strategic services that encompass investor relations, capital markets navigation, and corporate communications for innovative and emerging companies from around the globe. PCG Advisory has extensive experience with life science, fintech and blockchain technology companies.

PCG Advisory is part of PCG Holdings Inc., a holding company for a network of resources dedicated to the discovery and creation of value in the small and micro-cap equity market that was founded in 2008. All subsidiaries of PCG Holdings are geared toward helping investors identify value where it is not most obvious by facilitating a dynamic flow of information between its clients and the investment community.

PCG Holdings operating subsidiaries also includes PCG Digital and PCG Research. PCG Digital owns, partners with, and/or licenses innovative aggregation, distribution, and engagement platforms.  PCG Digital reaches thousands of individual, retail and institutional investors and stakeholders through its proprietary and extensive distribution network as well as through the use of unique multimedia marketing and audience development techniques.  PCG Digital, via its subsidiary, PCG Productions, produces management interviews and highlight and informational clips to further enhance and showcase our client companies. Videos are filmed at robust production resources in PCG’s NYC office.

PCG Research offers independent, issuer-sponsored research that is based on objective, fact-based analysis, written by experienced CFA analysts, and strategically distributed to the investment community utilizing targeted distribution channels as well as social media and private distribution relationships. For more information, go to www.pcgadvisory.com

Kirin Smith

President, PCG Advisory